Halozyme Therapeutics, Inc.
看多

Long oppertunity HALO Halozyme Therapeutics Inc (Mid-Term)

72
Company showing a great increase in fundamental strength and many good highlights
Fundamental
- Expect to strongly grow 50-70% Cashflow per share.
- Expect to 20% grow in one year.
- Turnover is rapidly growing.

免責聲明

這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。